欧盟批准Leqembi,一种新的阿尔茨海默氏病药物,在严格的条件下治疗早期患者。 EU approves Leqembi, a new Alzheimer's drug, for early-stage patients under strict conditions.

欧洲联盟委员会已经批准了Leqembi,这是由Biogen和Eisai在严格条件下为早期病人开发的一种新的阿尔茨海默氏治疗方法。 The European Commission has approved Leqembi, a new Alzheimer's treatment developed by Biogen and Eisai, for early-stage patients under strict conditions. Leqembi是在出于安全考虑初次拒绝后获得批准的,是第一种通过减少脑组织来显示阿尔茨海默氏病患者认知下降速度大幅放缓的药物。 Approved after initial rejection due to safety concerns, Leqembi is the first drug to show a significant slowing of cognitive decline in Alzheimer's patients by reducing brain plaques. 现已在所有27个欧盟国家以及挪威、冰岛和列支敦士登提供。 It is now available in all 27 EU countries plus Norway, Iceland, and Liechtenstein.